<DOC>
	<DOCNO>NCT02800668</DOCNO>
	<brief_summary>Implantation duodenal-jejunal endoluminal bypass liner ( DJBL ) show induce weight loss improve metabolic parameter . DJBL reversible endoduodenal sleeve mimic biliodigestive digestion lack risk limitation bariatric surgery . Effects metabolic control , body mass parameter , appetite regulation , glucose tolerance , organ health , lipid profile determine 16 morbidly overweight patient type 2 diabetes mellitus . In addition , relevant hormone ( Leptin , ghrelin , gastric inhibitory peptide , glucagon-like peptide 1 , insulin ) measure enzyme-linked immunosorbent assay ( ELISA ) chemiluminescent microparticle immunoassay ( CMIA ) 0 , 1 32 , 52 week post-implant follow mixed meal tolerance test , apply diagnostic purpose .</brief_summary>
	<brief_title>Metabolic Effects Duodenal Jejunal Bypass Liner Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>A total 18 subject ( 4 woman 14 men ) age 39 66 year underwent implantation DJBL.The subject regular patient Diabetes Center Herz- und Diabeteszentrum Nordrhein-Westfalen ( HDZ NRW ) , Germany give inform consent related procedure data handle . The subject body mass index ( BMI ) ≥35 kg/m2 , type 2 diabetes mellitus ( T2DM ) , history frustrate weight loss attempt . Exclusion criterion : history gastric surgery , gastric duodenal ulcer , thyroid disorder , gastrointestinal disorder associate intestinal resorption dysfunction , therapy oral anticoagulant like marcumar , use acetyl salicylic acid non-steroidal anti-inflammatory drug , drug abuse ( incl . alcohol ) , symptomatic cardiovascular disease include heart failure New York Heart Association ( NYHA ) IV , renal insufficiency define glomerular filtration rate ( GFR ) &lt; 50 ml/min , pregnancy breast feeding . Study design All patient receive DJBL due medical reason , study purpose . All patient underwent pre-implantation follow-up examination ( 1 week , 32 week 52 ( explantation ) week implantation ) . Every examination include thorough body examination , electrocardiogram ( ECG ) , body composition measurement bio-impedance scaling ( type : BC418MA , Tanita , Amsterdam , Netherlands ) . Upon implantation , antidiabetic medication adapt , patient follow adjust antidiabetic regimen . Dietary advice give patient professional dietician upon implantation procedure , liquid diet start day implantation continue two additional day follow puréed diet four day . Patients decide turn back normal diet upon tolerance ; fibre rich dietary component prohibit treatment period . Treatment glucagon-like peptide-1 ( GLP-1 ) dipeptidyl-peptidase-4 ( DPP4 ) base medication ( Exenatide , Liraglutide , Lixisenatide Sitagliptin , Vildagliptin ) initiate case fast C-peptide level &gt; 750 pmol/l . Insulin dosage reduce implantation avoid risk hypoglycaemia . Sulfonylurea treatment stop implantation . Mixed meal tolerance test Mixed meal tolerance test ( MMTT ) perform fast state routine diagnostic tool ass metabolism parameter gut hormone describe . In course MMTT every patient consume highly caloric drink ( Fortimel regular 2 093 Kilojoules ( KJ ) , Nutricia GmbH , Erlangen , Germany ) contain carbohydrate ( 41 energy ( EN ) % ) , proteins ( 40 EN % ) fat ( 19 EN % ) , simulate average meal . Blood sample take fixed interval : drinking , 10 , 30 , 60 , 90 , 120 min . DPP4 inhibitor add prevent autodigestion GLP-1 immediately sample , Hydroxymercuribenzoic acid add plasma per protocol prevent ghrelin digestion . Samples store centrifugation -80°C assay gut hormone ghrelin , GLP-1 , gastric inhibitory peptide , leptin well metabolism parameter glucose , insulin , C-peptide , proinsulin . Biochemical assessment Laboratory assessments do fast state . Venipuncture perform morning overnight fast one day plan procedure , one week , 8 , 12 month implantation . Blood sample process subsequent analysis within 20 min venipuncture . Serum concentration measure commercial available kit total ghrelin ( ELISA , Merck Chemicals Gesellschaft mit beschränkter Haftung ( GmbH ) , Schwalbach , Germany ) , leptin ( ELISA , DRG-International , Inc. , USA ) , active GLP-1 ( ELISA , epitope Diagnostics , San Diego , USA ) , gastric inhibitory Peptide ( GIP ) ( ELISA , DRG-International , Inc. , USA ) , Insulin ( CMIA , Abbott , Wiesbaden , Germany ) , C-peptide ( CMIA , Abbott , Wiesbaden , Germany ) , Proinsulin ( ELISA , TecoMedical Bunde , Germany ) glucose ( CMIA , Abbott , Wiesbaden Germany ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>T2DM body mass index ( BMI ) ≥35 kg/m2 history frustrate weight loss attempt history gastric surgery , gastric duodenal ulcer thyroid disorder gastrointestinal disorder associate intestinal resorption dysfunction therapy oral anticoagulant like marcumar use acetyl salicylic acid nonsteroidal antiinflammatory drug drug abuse ( incl . alcohol ) symptomatic cardiovascular disease include heart failure New York Heart Association IV renal insufficiency define GFR &lt; 50 ml/min pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Duodenal Jejunal Bypass Liner</keyword>
	<keyword>obesity</keyword>
	<keyword>weight loss therapy</keyword>
</DOC>